Glimiprex MF 2/500 Tablet PR is a fixed-dose combination medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The combination of these two agents offers complementary mechanisms of action, effectively lowering blood glucose levels in patients inadequately controlled by diet and exercise alone. Glimiprex MF 2/500 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. The medication is contraindicated in patients with renal or hepatic impairment, metabolic acidosis, or known hypersensitivity to either component. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. Patient adherence and periodic assessment of renal function are essential for safe and effective therapy with Glimiprex MF 2/500 Tablet PR.